Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report) traded down 3.5% on Monday . The company traded as low as $0.52 and last traded at $0.54. 249,673 shares traded hands during trading, a decline of 80% from the average session volume of 1,247,401 shares. The stock had previously closed at $0.56.
Elite Pharmaceuticals Stock Performance
The company has a current ratio of 4.88, a quick ratio of 3.50 and a debt-to-equity ratio of 0.08. The business has a 50-day simple moving average of $0.60 and a two-hundred day simple moving average of $0.51.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last posted its earnings results on Monday, June 30th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. Elite Pharmaceuticals had a positive return on equity of 3.96% and a negative net margin of 5.13%. The business had revenue of $32.00 million for the quarter.
About Elite Pharmaceuticals
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Featured Articles
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access